ERAMET (ER7.DE) Fundamental Analysis & Valuation

FRA:ER7 • FR0000131757

Current stock price

51.15 EUR
-2.55 (-4.75%)
Last:

This ER7.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ER7.DE Profitability Analysis

1.1 Basic Checks

  • ER7 had negative earnings in the past year.
  • ER7 had a negative operating cash flow in the past year.
  • ER7 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years ER7 4 years had a positive operating cash flow.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • ER7 has a Return On Assets of -1.58%. This is in the lower half of the industry: ER7 underperforms 70.45% of its industry peers.
  • The Return On Equity of ER7 (-9.29%) is worse than 79.55% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 0.80%, ER7 is doing worse than 68.18% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ER7 is in line with the industry average of 8.75%.
  • The last Return On Invested Capital (0.80%) for ER7 is well below the 3 year average (7.29%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROIC 0.8%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

  • ER7's Profit Margin has declined in the last couple of years.
  • With a Operating Margin value of 1.91%, ER7 is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
  • ER7's Operating Margin has declined in the last couple of years.
  • ER7's Gross Margin of 68.15% is amongst the best of the industry. ER7 outperforms 88.64% of its industry peers.
  • In the last couple of years the Gross Margin of ER7 has grown nicely.
Industry RankSector Rank
OM 1.91%
PM (TTM) N/A
GM 68.15%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ER7.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ER7 is destroying value.
  • Compared to 1 year ago, ER7 has more shares outstanding
  • The number of shares outstanding for ER7 has been increased compared to 5 years ago.
  • ER7 has a better debt/assets ratio than last year.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • Based on the Altman-Z score of 1.09, we must say that ER7 is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.09, ER7 is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 2.03 is on the high side and indicates that ER7 has dependencies on debt financing.
  • ER7's Debt to Equity ratio of 2.03 is on the low side compared to the rest of the industry. ER7 is outperformed by 90.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Altman-Z 1.09
ROIC/WACC0.09
WACC9.26%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that ER7 should not have too much problems paying its short term obligations.
  • ER7 has a Current ratio of 1.54. This is in the lower half of the industry: ER7 underperforms 70.45% of its industry peers.
  • ER7 has a Quick Ratio of 1.06. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
  • ER7 has a Quick ratio of 1.06. This is comparable to the rest of the industry: ER7 outperforms 45.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.06
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ER7.DE Growth Analysis

3.1 Past

  • The earnings per share for ER7 have decreased strongly by -219.63% in the last year.
  • ER7 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -64.00% yearly.
  • The Revenue has decreased by -6.91% in the past year.
  • ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%

3.2 Future

  • ER7 is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -55.03% yearly.
  • The Revenue is expected to grow by 6.17% on average over the next years.
EPS Next Y-333.81%
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%
EPS Next 5Y-55.03%
Revenue Next Year4.29%
Revenue Next 2Y6.01%
Revenue Next 3Y6.87%
Revenue Next 5Y6.17%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. ER7.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ER7. In the last year negative earnings were reported.
  • ER7 is valuated quite expensively with a Price/Forward Earnings ratio of 56.17.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ER7 indicates a slightly more expensive valuation: ER7 is more expensive than 72.73% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of ER7 to the average of the S&P500 Index (23.84), we can say ER7 is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 56.17
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • ER7's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.86
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

  • ER7's earnings are expected to decrease with -6.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ER7.DE Dividend Analysis

5.1 Amount

  • ER7 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ER7.DE Fundamentals: All Metrics, Ratios and Statistics

ERAMET

FRA:ER7 (3/13/2026, 7:00:00 PM)

51.15

-2.55 (-4.75%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)02-18
Earnings (Next)04-23
Inst Owners14.01%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.47B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts80
Price Target61.41 (20.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.57%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-28%
EPS NY rev (3m)-2269.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)5.29%
Revenue NY rev (3m)1.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 56.17
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB 2.72
EV/EBITDA 14.86
EPS(TTM)-3.42
EYN/A
EPS(NY)0.91
Fwd EY1.78%
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROCE 1.16%
ROIC 0.8%
ROICexc 0.95%
ROICexgc 1.09%
OM 1.91%
PM (TTM) N/A
GM 68.15%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Debt/EBITDA 10.29
Cap/Depr 403.31%
Cap/Sales 21.11%
Interest Coverage 0.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.06
Altman-Z 1.09
F-Score2
WACC9.26%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-333.81%
EPS Next 2Y-53.42%
EPS Next 3Y-6.49%
EPS Next 5Y-55.03%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year4.29%
Revenue Next 2Y6.01%
Revenue Next 3Y6.87%
Revenue Next 5Y6.17%
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year-4.34%
EBIT Next 3Y30.08%
EBIT Next 5Y23.12%
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ER7.DE Fundamental Analysis FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.


Can you provide the valuation status for ERAMET?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.


What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.


Can you provide the financial health for ER7 stock?

The financial health rating of ERAMET (ER7.DE) is 2 / 10.


How sustainable is the dividend of ERAMET (ER7.DE) stock?

The dividend rating of ERAMET (ER7.DE) is 0 / 10 and the dividend payout ratio is -44.33%.